The Technical Analyst
LifeSci Acquisition II [LSAQ]
Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
LifeSci Acquisition II Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.96% $9.01
America/New_York / 7 okt 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 051.73 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 116.73 mill |
| Avg Daily Volume: | 0.0366 mill |
| RATING 2022-01-31 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -18.15 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -25.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.93 - 9.09 ( +/- 0.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-08-25 | Mcdonald Andrew I | Sell | 138 591 | Common Stock |
| 2021-08-25 | Rice Michael Yehuda | Sell | 138 591 | Common Stock |
| 2020-11-24 | Rice Michael Yehuda | Buy | 3 146 453 | Warrants |
| 2020-11-24 | Mcdonald Andrew I | Buy | 3 146 453 | Warrants |
| 2020-11-20 | Janssen Scott | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 7 transactions |
| Buy: 6 292 906 | Sell: 277 182 |
Forecast:
01:40 - $9.83
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.01 (-1.96% ) |
| Volume | 0.0417 mill |
| Avg. Vol. | 0.0366 mill |
| % of Avg. Vol | 113.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LSAQ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LSAQ
LifeSci Acquisition II Corp. intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities in the healthcare industry. The company was founded in 2019 and is based in New York, New York.
Latest Press Releases
2020-11-20 13:51:00 - Press Release
Lifesci Acquisition Ii Corp. Announces Pricing Of $75 Million Initial Public Offering
New york, nov. 20, 2020 (globe newswire) -- lifesci acquisition ii corp. (nasdaq: lsaq), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. the shares will begin trading today on the nasdaq capital market (“nasdaq”) under the symbol “lsaq.”
Latest News
2023-03-13 08:41:32 - InvestorPlace
Why Is Science 37 (SNCE) Stock Up 9% Today?
Science 37 (NASDAQ: SNCE ) stock is rising higher on Monday following news of inducement equity awards for its Metasite employees. According to a press release from Science 37, the awards were approved by its Board of Directors in November 2022.
2022-03-22 10:44:05 - Seeking Alpha
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
2022-01-02 15:05:22 - Seeking Alpha
Science 37: Pioneering Decentralized Clinical Trials
Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs.
2021-05-08 16:16:41 - Benzinga
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
2020-11-22 13:07:23 - Seeking Alpha
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals, which soared 158% on its first day. New filings continued to pour in, priming the IPO pipeline for an active end to 2020.
2020-11-20 13:51:00 - GlobeNewsWire
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. The shares will begin trading today on the NASDAQ Capital Market (“NASDAQ”) under the symbol “LSAQ.”